

## Special Issue

# Recent Advances in the Clinical Outcome of Chronic Hepatitis B Patients

### Message from the Guest Editor

During the past several decades we have witnessed major progress in all areas of hepatitis B virus (HBV) biology, including replication, pathobiology and antiviral therapy. Investigations on viral DNA replication have uncovered covalently closed circular DNA (cccDNA) amplification as the mechanism for HBV persistence. Studies in animal models have demonstrated that viral clearance is associated with a strong cytotoxic T-cell response that can destroy infected hepatocytes. Nucleos(t)ide analogues block viral replication, but they cannot cure chronic HBV infections and prevent the development of hepatocellular carcinoma. The ultimate goals of this Special Issue are not only to obtain a more precise understanding of the HBV life cycle, but also to acquire an understanding that will lead to more effective treatments and pathogenic process. Furthermore, another ambitious aim of this Issue is to explore the significant clinical role of HBV infection in relevance with the current public health problems and new medical needs.

### Guest Editor

Dr. Hariklia Kranidioti

2nd Academic Department of Internal Medicine, General Hospital of Athens "Hippokratio", Medical School of National and Kapodistrian University of Athens, Athens, Greece

### Deadline for manuscript submissions

closed (30 June 2023)



## Livers

an Open Access Journal  
by MDPI

Impact Factor 2.4  
CiteScore 3.2



[mdpi.com/si/118484](https://mdpi.com/si/118484)

*Livers*

Editorial Office  
MDPI, Grosspeteranlage 5  
4052 Basel, Switzerland  
Tel: +41 61 683 77 34  
[livers@mdpi.com](mailto:livers@mdpi.com)

[mdpi.com/journal/](https://mdpi.com/journal/)

[livers](https://mdpi.com/journal/livers)





# Livers

---

an Open Access Journal  
by MDPI

---

Impact Factor 2.4  
CiteScore 3.2



[mdpi.com/journal/  
livers](https://mdpi.com/journal/livers)

## About the Journal

### Message from the Editor-in-Chief

---

#### Editor-in-Chief

Prof. Dr. Hartmut W. Jaeschke

Department of Pharmacology, Toxicology & Therapeutics, University of  
Kansas Medical Center, Kansas City, KS 66160, USA

---

#### Author Benefits

##### High Visibility:

indexed within ESCI (Web of Science), Scopus, EBSCO,  
and other databases.

##### Rapid Publication:

manuscripts are peer-reviewed and a first decision is  
provided to authors approximately 27.8 days after  
submission; acceptance to publication is undertaken in 6.7  
days (median values for papers published in this journal in  
the first half of 2025).

##### Recognition of Reviewers:

APC discount vouchers, optional signed peer review, and  
reviewer names published annually in the journal.

